Members of the Clinical Research Strategy Group at the Prostate Cancer UK headquarters
Next CRSG meeting:
📅Fri 17 Apr 2026,
🚩London.
Details 👇
🔗 prostatecanceruk.org/research/for...
🧵[5/6]
💡 Got a new trial idea to improve outcomes for men with prostate cancer?
Use our form and submit your proposal
Deadline: 4pm, Fri 13 Feb
Applicants are encouraged to present their ideas and take part in the discussion at the next CRSG meeting.
prostatecanceruk.org/research/for...
🧵[4/6]
🌱 Early-career clinical researchers — your opportunity is here!
Apply for one of two CRSG observer roles to learn from leaders, connect nationally & grow your research career in prostate cancer.
Deadline: 4pm, Fri 16 Jan
🧵[3/6]
👥 We’re recruiting Full Members!
Expertise wanted in:
🧬 Pathology
🏥 Primary care
💉 Research nursing
🩻 Radiology
Join us in shaping UK prostate cancer clinical research.
Deadline: 4pm, Fri 16 Jan
🧵[2/6]
The CRSG will shape clinical prostate cancer research by:
🔍 Identifying key research gaps
💪 Strengthening study design early
👏 Encouraging collaboration
🧑🎓 Mentoring early-career researchers
🧵[1/6]
📣 Big news for clinical prostate cancer researchers!
The NCRI Prostate Group has re-established as UK Prostate Cancer Clinical Research Strategy Group (CRSG) - a national hub for collaboration & innovation in prostate cancer research.
Learn more 👇
prostatecanceruk.org/research/for...
As debate grows over targeted #ProstateCancer screening, experts call for careful evaluation.
"We can often find disease that doesn't need to be treated and we end up causing harm" — Prof Hashim Ahmed (@londonprostate1.bsky.social)
@imperialsandc.bsky.social www.bbc.co.uk/news/article...
Update of #IP7PACIFIC presented by @ajwlight.bsky.social at #AUA25 🇺🇸
This will be the first trial to provide definitive evidence comparing bpMRI vs mpMRI, alongside fusion vs cognitive biopsy
>1200 patients recruited across the UK - watch this space
Update of #IP9ATLAS presented by Archana Gopalakrishnan at #AUA25 🇺🇸
This pivotal RCT will evaluate MRI-based surveillance for patients with GG1-2 cancer starting active surveillance
Recruitment is open across the UK!
That’s a wrap on #AUA25 for Team IP!
See you in Washington DC for #AUA26! 🇺🇸
New publication alert! 🚨
A clinician survey on the current practices within the prostate cancer diagnostic pathway in the United Kingdom - Uma Walters et al (Journal of Clinical Urology)
🔗 doi.org/10.1177/2051...
5yr outcomes following Rezum for >80mL prostates presented by @ajwlight.bsky.social (on behalf of Yan Leung) #AUA25 🇺🇸
Take home message - 3 of 4 patients were free of retreatment by 5 years
Excellent podium presentation by our resident Chase Ng on >1200 patients in #RAPID discharged with negative MRI or biopsy
Only 1 in 12 developed csPCa & 1 in 20 needed cancer treatment by 5 years
More evidence of the oncological efficacy of pre-biopsy MRI! #AUA25 🇺🇸
@ajwlight.bsky.social presents preliminary validation data on the #TARGET scoring system - good specificity and NPV for detecting GG2+ in-field disease
Watch this space for our definitive multi centre validation study! #AUA25 🇺🇸
Building on our #IP8FLUORESCE study is #IB1LaserCOMPLETE - using ex vivo fluoresce confocal microscopy to establish muscle status in TURBT, presented by Archana Gopalakrishnan
Recruitment is under way - watch this space for results soon! #AUA25 🇺🇸
In further #RAPID data, Chase Ng shows that patients discharged from a pre-biopsy MRI pathway with ASAP or HGPIN do not have a greater risk of subsequent csPCa or treatment than patients discharged without
#AUA25 🇺🇸
Powerful messages from @londonprostate1.bsky.social in the focal therapy plenary crossfire debate
Most intermediate risk cases are suitable, focal therapy is very effective, and the functional outcomes are superior. Surgeon training is crucial!
#AUA25 🇺🇸
Pilot results from #IP2ATLANTA on novel cytoreductive treatments to the prostate & mets in de novo mHSPC presented by @londonprostate1.bsky.social #AUA25 🇺🇸
Take home - these treatments are safe and justified
Recruitment for the main trial has completed - PFS endpoint to be reported 2027
Thanks. Appreciate the kind words.
📢 Join us at @IP_London
We are recruiting a Clinical Research Fellow to join the #IP13AVIDITY team: RCT evaluating the role of PSMA PET/CT in directing treatment in patients w/ high-risk PCa (closing 15/04)
🔗 www.imperial.ac.uk/jobs/search-...
@londonprostate1.bsky.social @connorurol.bsky.social
💬 #TRANSFORM will look at new ways of screening to reduce false positives, reduce biopsy rates and reduce diagnosing low risk cancers whilst finding more high risk cancers that need treating.
@londonprostate1.bsky.social @prostatecanceruk.bsky.social @nihr.bsky.social
www.lbc.co.uk/opinion/view...
Great to see Professor Hashim Ahmed @londonprostate1.bsky.social talking @nickferrarilbc.bsky.social through his PSA blood test this morning, and sharing why the TRANSFORM trial is vital for finding the best way to screen men for #ProstateCancer.
prostatecanceruk.org/research/tra...
Two weeks to go!
Imperial Prostate Masterclass
In association with Focal Therapy Society
@ip-london.bsky.social
www.imperialprostatemasterclass.org
With presentations from 4 IP trials and multiple other projects, it’s been a fantastic #EAU25 for Imperial Prostate 🇪🇸
See you next year in London for #EAU26! 🇬🇧
#IP2ATLANTA RCT pilot result #EAU25 🇪🇸
🔬 9 in 10 patients have a viable prostate tumour despite ADT+ARTA/Doce
🚦Early signal in prostate cancer mortality for cytoreductive arms
📈 Surgery, radiotherapy or ablation + SABR safe - Recruited (n=433) PFS exp.2027!
@connorurol.bsky.social
It’s a big last day at #EAU25 for our team! 🇪🇸
@connorurol.bsky.social - 2x #IP2ATLANTA pilot study results (12:00)
Mr Chase Ng - #RAPID 5-yr follow-up for negative biopsy patients (12:05)
Mr Nikhil Mayor - #IP8FLUORESCE late breaking results (12:15)
Mr Chase Ng presents 5-year follow-up data for patients discharged with negative MRI/biopsy from our #RAPID pathway #EAU25 🇪🇸
1 in 12 were subsequently diagnosed with GG2+ cancer and 1 in 20 needed treatment - this further highlights the efficacy of MRI-based diagnostics!
Building on this morning’s #NeuroSAFE data, @nikhilmayor.bsky.social presents late-breaking results from #IP8FLUORESCE, assessing the diagnostic accuracy of FCM for detecting positive margins intra-op
Feasible, quick and good sensitivity and specificity for detecting margins ≥3mm!
#EAU25 🇪🇸
Nice work by Deepika! #EAU2025 #EAU25
Lastly for Imperial Prostate today @ #EAU25 🇪🇸 is Ms Deepika Reddy in the new technologies & focal therapy in localised PCa session
Traditional risk classification strategies developed for radical treatment are not transferrable to focal therapy outcomes. Risk models are in development!
